In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher ... a powerful factor that could impact its near-term stock price. The earnings report, which is expected ...

This was the stock's second consecutive day of losses.

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Stock rises ... offsetting the decline. Dupixent remains a growth driver with global net sales up 19% to $3.67 billion, although these sales are booked by Sanofi. Regeneron's share of profits ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product ... down 6.8% from previous close. The stock market overreacts to news, and ...

The stock's fall snapped a two-day winning streak.